# DURGA-6: HCP commentary report

> 61 verified statements (57 from clinicians verified by NPI or staff page) from 4 commentary sources · 8 findings · updated Oct 30, 2026

## Report

- Trial: A Phase III, Open-label, Multicentre, Randomised Study Comparing Consolidation Treatment With AZD0120, an Autologous Dual Targeting Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, Versus Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (TE NDMM) (DURGA-6)
- NCT ID: NCT07735637
- Registry: https://clinicaltrials.gov/study/NCT07735637
- Sponsor: AstraZeneca
- Phase: Phase 3
- Status: Recruiting
- Drugs tested: AZD0120
- Indication: transplant-eligible newly diagnosed multiple myeloma
- Version: v1.0.0, edition 1
- Accepted: 2026-10-30
- Last checked: 2026-10-30
- Release hash: d403eadb649c8c187db8b68808b8f3d2d79c7a9d805aab97ab66c180db60a0b1

## Counts

- HCP commentary sources screened: 14
- Sources cited by verified statements: 4
- Verified statements: 61
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 57
- Findings: 8
- Named people in screened sources (unnamed speakers and accounts not counted): 6
- Voices cited: 6
- Cited voices identity-verified: 6

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

DURGA-6 compares AZD0120 CAR-T consolidation with autologous stem cell transplantation in transplant-eligible patients with newly diagnosed multiple myeloma. Commentary comes from X posts, a podcast and YouTube discussions featuring physicians, including medical oncologists, and a hematology–oncology nurse practitioner. Debate centers on whether CAR-T will displace transplantation, an unsettled prospect, and how sustained MRD negativity should be interpreted. Another question is whether rapid manufacturing offers biological advantages, which remain hypothetical in these discussions.

## Open Medical Affairs question

What evidence and support would make CAR-T a replacement for ASCT rather than another individualized consolidation option?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. ASCT displacement is a forecast, not a settled replacement strategy
- F2. Earlier Chinese frontline findings generate enthusiasm, but are not DURGA-6 outcomes
- F3. Sustained MRD negativity is the interpretive priority, not a single negative sample
- F4. Rapid manufacturing and dual targeting attract interest, while biological advantages remain hypotheses
- F5. Eligibility and access depend on fitness, manufacturing time, preference and early collaboration
- F6. The manufacturing interval remains a treatment-sequencing problem
- F7. A single infusion and outpatient delivery do not eliminate continuing care
- F8. Early toxicity treatment is described as evolving institutional practice, not an AZD0120 protocol

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 10 | 12 | 2 | 4 | recorded | 4 |
| F2 | 4 | 4 | 1 | 1 | none recorded | 4 |
| F3 | 4 | 4 | 1 | 2 | none recorded | 3 |
| F4 | 6 | 4 | 2 | 3 | none recorded | 3 |
| F5 | 6 | 3 | 1 | 2 | none recorded | 3 |
| F6 | 5 | 2 | 2 | 1 | none recorded | 3 |
| F7 | 6 | 6 | 2 | 3 | recorded | 4 |
| F8 | 13 | 5 | 3 | 2 | none recorded | 5 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 2 | 2 | 0 | 0 | 6 | 13 | 7 | 1 post or article, 1 podcast or video | yes |
| F2 | 3 | 0 | 0 | 0 | 1 | 4 | 3 | 1 podcast or video | yes |
| F3 | 3 | 1 | 0 | 0 | 0 | 4 | 1 | 1 podcast or video | yes |
| F4 | 3 | 1 | 0 | 2 | 0 | 6 | 0 | 2 podcasts and video | yes |
| F5 | 3 | 0 | 2 | 1 | 0 | 6 | 0 | 1 podcast or video | yes |
| F6 | 0 | 0 | 3 | 0 | 2 | 5 | 0 | 2 podcasts and video | yes |
| F7 | 1 | 0 | 1 | 2 | 2 | 6 | 0 | 2 podcasts and video | yes |
| F8 | 4 | 0 | 2 | 0 | 7 | 15 | 1 | 3 podcasts and video | yes |

### Trial dimensions

- Primary endpoint: Progression-Free Survival (PFS): no finding draws on it directly
- Primary endpoint: Minimal Residual Disease (MRD) negative Complete Response Rate (CRR): F3 (4 shared claims)
- Secondary endpoints: F2 (2 shared claims)
- Population and setting: F2 (1 shared claims), F5 (5 shared claims), F7 (1 shared claims)
- The comparison: F1 (8 shared claims), F5 (1 shared claims), F7 (2 shared claims)
- Safety and tolerability: F2 (1 shared claims), F7 (1 shared claims), F8 (13 shared claims)
- Design and conduct: no finding draws on it directly

## Sample findings

Paraphrased; the full report links each statement to its source.

### F3. Sustained MRD negativity is the interpretive priority, not a single negative sample

In a YouTube discussion, a medical oncologist asked how sustained MRD negativity should be interpreted in the earlier Chinese frontline study.

Source: YouTube video, 2026-08-03.

### F4. Rapid manufacturing and dual targeting attract interest, while biological advantages remain hypotheses

In the YouTube discussion, the same medical oncologist asked whether FasT-CAR manufacturing could improve efficacy in addition to shortening production time.

Source: YouTube video, 2026-08-03.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 8 | Titles free |
| Detailed analysis | 9 sections | Paid |
| Verified statements with short source quotes and links | 61 | Paid |
| Trial aspects mapped | 12 | Free |
| Sources with links | 4 | Counts free |
| Speaker attribution for cited voices | 6 | Paid |

## Trial aspects

10 discussed · 2 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Progression-Free Survival (PFS) | no commentary found | 0 | 0 |
| Primary endpoint: Minimal Residual Disease (MRD) negative Complete Response Rate (CRR) | discussed | 4 | 1 |
| Secondary endpoints | discussed | 2 | 1 |
| Population and setting | discussed | 7 | 2 |
| The comparison | discussed | 10 | 3 |
| Safety and tolerability | discussed | 14 | 3 |
| Design and conduct | no commentary found | 0 | 0 |
| Manufacturing speed and dual-target biological rationale | discussed | 6 | 2 |
| Local access, patient preference and early collaborative referral | discussed | 7 | 2 |
| Pre-apheresis treatment, bridging and lymphodepletion planning | discussed | 5 | 2 |
| Continuing care, caregiver support and outpatient feasibility | discussed | 5 | 2 |
| Future treatment roles, access expectations and uncertainty about a single replacement pathway | discussed | 14 | 4 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 11 | 1 |
| YouTube | 2 | 2 |
| Podcasts | 1 | 1 |

- Screened window: 2026-08-01 to 2026-09-27
- Cited window: 2026-08-03 to 2026-09-23
- Retrieved: 2026-10-30

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase III, Open-label, Multicentre, Randomised Study Comparing Consolidation Treatment With AZD0120, an Autologous Dual Targeting Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, Versus Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (TE NDMM) (DURGA-6)
- Registry: NCT07735637 (https://clinicaltrials.gov/study/NCT07735637)
- Study IDs: D8316C00001 · AZD0120 (AstraZeneca)
- Sponsor: AstraZeneca
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Recruiting
- Enrollment: 750 (estimated)
- Start: 2026-09-24 (actual)
- Primary completion: 2028-11-02 (estimated)
- Primary endpoint: Progression-Free Survival (PFS) (Up to approximately 13 years.)
- Primary endpoint: Minimal Residual Disease (MRD) negative Complete Response Rate (CRR) (Up to approximately 13 years.)
- Intervention: AZD0120 (biological)
- Intervention: Cyclophosphamide (drug)
- Intervention: Fludarabine (drug)
- Intervention: Melphalan (part of ASCT) (drug)
- Intervention: Lenalidomide (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Some clinician views in the sources used in this report are not yet captured as evidence in this edition.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 76 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The sources reviewed for this edition provide perspectives from a small set of conversations, not a representative measure of HCP opinion. Podcast and video versions of the ONS session must not be counted as independent support.
- No publication of results for NCT07735637 was found, and no protocol was available among the sources reviewed. The report cannot establish comparative efficacy, trial-specific safety or detailed protocol requirements.
- Earlier Chinese frontline findings include both transplant-eligible and transplant-ineligible patients. Their favorable interpretation does not establish benefit over ASCT in DURGA-6.
- Several treatment-choice statements do not name DURGA-6. They are contextual views on the relevant clinical decision, not direct evaluations of the trial's outcomes or conduct.
- Some podcast remarks about future treatment roles do not identify who spoke. Those passages remain unnamed and are not treated as additional independent views.
- Discussion using unnamed trial references, alternative terminology or different transcriptions may be missing, and some additional X material was not fully assessed.
- No exact AZD0120 product label was located, and the broader regulatory review was incomplete. General CAR-T practices in these discussions cannot be treated as AZD0120 prescribing instructions.
- The safety discussion is selective: the institutional policy on prophylactic tocilizumab and concerns about prolonged cytopenias, clonal marrow changes and secondary malignancies are not characterized here. This limits conclusions about preventive care and long-term safety.
- Not yet captured in this edition: a view on geographic CAR T access barriers and developing CAR T capacity at transplant centers.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-30: current edition, corrected 2026-10-30
  - Correction 2026-10-30: Corrected to match the delivered report: the limitations; the sample findings; the report description.

Last checked for new commentary 2026-10-30. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (61 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (6 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/durga-6-nct07735637
- Agents: POST https://www.erudio.com/api/orders with {"report": "durga-6-nct07735637", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=durga-6-07735637

## Cite

Erudio Health. DURGA-6 (NCT07735637): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 30, 2026. https://www.erudio.com/reports/durga-6-nct07735637

## Machine access

- JSON: https://www.erudio.com/reports/durga-6-nct07735637.json
- Markdown: https://www.erudio.com/reports/durga-6-nct07735637.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "durga-6-07735637"}`